GlassScriptPhysician profile
Robert James Theobald
NPI 1396778239
$3,804.76
in general payments reported to CMS, 2019-2025
20 companies · $20.24 in 2025
The $20.24 reported for 2025 was less than what a typical Colon & Rectal Surgery provider received nationally (typical 2025 total: $317).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,824 · 2020: $812 · 2021: $471 · 2022: $279 · 2023: $172 · 2024: $226 · 2025: $20.24.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $418.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Concordia Pharmaceuticals INC. | $741.14 | 2019 | |
| Napo Pharmaceuticals INC | $709.36 | 2019 | |
| Zyla Life Sciences, INC. | $689.96 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $525.05 | 2019-2024 | Trulance |
| Redhill Biopharma INC. | $273.91 | 2020-2021 | |
| Ironwood Pharmaceuticals, INC | $273.01 | 2020-2024 | Linzess |
| Merck Sharp & Dohme LLC | $175.74 | 2021-2025 | Bridion |
| Takeda Pharmaceuticals U.S.A., INC. | $45.83 | 2019-2021 | |
| Heron Therapeutics, INC. | $43.92 | 2021-2022 | |
| Acell, INC. | $42.82 | 2019 | |
| Innocoll Pharmaceuticals Limited | $41.99 | 2021-2022 | |
| Pacira Pharmaceuticals Incorporated | $38.72 | 2020-2024 | Exparel |
| Medtronic USA, INC. | $38.34 | 2019 | |
| Kci USA, INC. | $36.50 | 2020-2021 | |
| Abbvie INC. | $31.16 | 2024 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Angiodynamics, INC. | $27.50 | 2020 | |
| Teleflex LLC | $21.06 | 2019 | |
| Smith+Nephew, INC. | $20.17 | 2019 | |
| Alfasigma USA, INC. | $14.92 | 2020 | |
| Kowa Pharmaceuticals America, INC. | $13.66 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Theobald listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.